Diatherix Acquires TEM-PCR Patent from Qiagen; Expands Business Model | GenomeWeb

NEW YORK (GenomeWeb News) – Diatherix Laboratories today announced it has acquired from Qiagen a patent covering technology for rapidly identifying multiple infectious disease organisms.

The acquisition of the patent for the technology called TEM-PCR follows a multiyear licensing agreement between Diatherix and Qiagen. Diatherix said that it and Qiagen are working on distribution and supply agreements to continue their partnership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."